See associations below
|I CEA||CEA carcinoembryonic antigen|
|I CDX2||CDX2 colorectal carcinoma|
|I CK5/6||Cytokeratinj 5/6, positive squamous, mesothelia|
|I CK7||Cytokeratin 7, 54kD|
|I CK HMW||34BE12, Cytokeratin high molecular weight|
|I CAM52||Cytokeratin 8 (CAM5.2)|
|I CK8/18||Cytokeratin 8/18|
|I CK20||Cytokeratin 20|
|I D2 40||D2-40, Podoplanin|
|I GCDFP15||Gross cystic disease fluid protein 15|
|I HEPAR1||Hepatocyte antigen (HEP-Par-1), liver|
|I RCC||Renal cell carcinoma|
|I CK8||Cytokeratin 8, 35BH11|
|I CK19||Cytokeratin 19|
|I GALECT||Galectin-3, thyroid neoplasm, anaplastic LCL|
|I TTF1||Thyroid transcription factor-1, lung, thyroid|
|I INHIB||Inhibin, adrenal cortical, sex chord stromal|
|I PLAP||Placental alkaline phosphatase, germ cell tumor|
Technical component (TC) available for all markers
Paraffin embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass
Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen.
Inadequate fixation; Improper labeling
Marker and tissue specific
Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment.
Immunohistochemistry combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining.
MPLN offers a range of markers by Immunohistochemistry including hematologic, tissue specific, infectious agents and proliferation antigens.